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Objective: This study was undertaken to compare the clinical and hemodynamic
results following aortic valve replacement with a pulmonary valve autograft (Ross
procedure) or an allograft valve in children.
Methods: The records of 107 pediatric aortic valve replacements from 1994 through
2001 were reviewed, including 78 autografts and 25 allografts. Four mechanical
aortic valve replacements performed during this period were excluded from analy-
sis.
Results: There were 3 perioperative deaths and 1 late death. Reoperations were
required in 5 autograft recipients (with autograft preservation in 4) and in 3 allograft
recipients (all requiring valve re-replacement). Seven-year survival (96% in both
groups) and reoperation-free survival (88% in the autograft group; 73% in the
allograft group, P  .5) were not significantly different. Serial echocardiographic
studies showed that in the autograft group, left ventricular outflow tract maximal
velocity (2.0-1.8 m/s, P  .02) and left ventricular thickness (10.1-8.4 mm, P 
.0001) fell significantly. In the allograft group, maximal velocity (2.3-3.0 m/s, P 
.03) increased significantly and left ventricular thickness (9.5-9.0 mm, P  .2)
showed minimal change. Analysis according to preoperative physiology (aortic
stenosis versus insufficiency), congenital cardiac anatomy, number or type of
previous operations, age of patient, and use of balloon valvotomy did not predict
outcomes.
Conclusions: Aortic valve replacement with either the autograft or allograft provides
excellent clinical results in children during an intermediate duration of observation.
The Ross procedure achieves a superior hemodynamic result, which may be clini-
cally important with longer follow-up.
For children requiring aortic valve replacement (AVR), the pulmonaryvalve autograft, or Ross procedure, has become increasingly acceptedas the operative approach of choice. For some patients, however, theRoss procedure is impossible or perhaps ill advised. The pulmonaryvalve may be congenitally absent or deformed, damaged by acquireddisease, or compromised by previous surgical procedures. Further-
more, certain connective tissue disorders, such as Marfan syndrome, probably affect
the pulmonary valve and disqualify it from consideration for autografting. In such
patients, allograft valves can be used effectively, as they have been for many years
in adult populations.
It is not known how well autograft and allograft valves compare in the pediatric
population. To better understand the long-term clinical and hemodynamic conse-
quences of these 2 forms of AVR, we analyzed a large clinical series from a single
institution.
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The medical records of all patients undergoing AVR from January
1, 1994, through December 31, 2001, at Children’s Hospital in
Seattle, Washington, were reviewed. Demographic data, informa-
tion regarding congenital and acquired cardiac malformations,
preoperative treatment and interventions, operative details, and
postoperative outcomes were recorded. Patients, families, cardiol-
ogists, and primary care physicians were contacted when necessary
to acquire current follow-up information. Permission for perform-
ing this study was obtained from the institutional review board.
This report includes patients who were the subjects of a previous
publication.1
Echocardiography
Transthoracic echocardiographic findings were recorded from all
patients’ studies performed subsequent to valve replacement. Left
ventricular posterior wall thickness in diastole was recorded from
M-mode measurements according to standard methods. Maximal
left ventricular outflow velocity was recorded by continuous wave
Doppler interrogation of flow across the left ventricular outflow
tract. The greatest maximal velocity (Vmax) measured (generally
obtained from either the apical or suprasternal notch view) was
recorded. Neoaortic valve insufficiency was evaluated by a color
Doppler flow map in the left ventricular outflow tract and graded
on a 0 or trace to 4 scale. Comparisons were made between the
patients’ postoperative echocardiographic indices obtained during
hospitalization for their AVRs and their most recently obtained
measurements.
Statistical Analysis
Mean values and standard deviations were calculated for contin-
uous variables. Comparisons were made between recipients of
autografts and allografts with respect to survival and reoperation-
free survival using Kaplan-Meier methods and the log-rank test.
Comparisons were made with respect to echocardiographic indices
using paired and unpaired t tests as appropriate. Contingency table
analysis was used to compare the preoperative pathophysiology in
the 2 groups. All analyses were performed using StatView statis-
tical software (Abacus Concepts, Berkeley, Calif).
Results
Patient Characteristics
During the 8-year period from 1994 to 2001, 107 AVRs
were performed. Four operations consisted of AVR with a
mechanical valve; a mechanical valve was used because of
the size of the aortic valve annulus, impossibility of per-
forming a Ross procedure, and unavailability of a suitable
allograft. These recipients of mechanical AVRs were ex-
cluded from further analysis. The remaining 103 operations,
including 78 autograft AVRs and 25 allograft AVRs, form
the basis for this study. Patient ages were from 0.2 to 22.3
years (mean 10.6 years) with body weights from 3.6 to
129.3 kg (mean 41.8 kg). The mean ages (autograft: 10.7 
6.6 years; allograft: 10.2  5.5 years) and weights (au-
tograft: 42.9  28.9 kg; allograft 38.2  23.4 kg) of the 2
subgroups were not significantly different. AVR with an
autograft was considered the preferred operative approach
and was undertaken in all cases where there were no obsta-
cles to retrieval of the pulmonary valve. In the 25 allograft
AVRs (22 aortic valve allografts, 3 pulmonary valve allo-
grafts), the decision not to perform an autograft AVR was
made for the following reasons: previous operative proce-
dures that compromised the pulmonary valve in 12 cases,
congenital absence or deformity in 8 cases (7 truncus arte-
riosus, 1 tetralogy of Fallot), Marfan syndrome in 4 cases,
and endocarditis involving the pulmonary valve in 1 case.
The congenital cardiac anatomy of the patients is shown
in Table 1, separated by type of AVR, autograft or allograft.
The autograft group had a preponderance of congenital
aortic valve stenosis, whereas the allograft group exhibited
a more diverse group of congenital diagnoses.
Patients’ pathologic diagnoses at the time of AVR are
shown in Table 2, separated by type of AVR. Autograft
patients had a much greater frequency of mixed aortic
stenosis and insufficiency than did allograft recipients. The
difference in distribution of pathologic lesions was signifi-
cantly different by 2 analysis (2  17.2948, P  .0002).
TABLE 1. Congenital and acquired cardiac diagnoses (primary diagnoses only)
Autograft (n  78) Allograft (n  25)
Congenital anomalies Congenital anomalies
Aortic valve stenosis (60) Truncus arteriosus (7)
Ventricular septal defect (4) Aortic valve stenosis (6)
Aortic valve insufficiency (3) Marfan’s syndrome (4)
Subaortic stenosis (3) Ventricular septal defect (2)
Interrupted aortic arch (2) Interrupted aortic arch (1)
Supravalvar aortic stenosis (1) Supravalvar aortic stenosis (1)
Left ventricular-aortic tunnel (1) Transposition of the great arteries (1)
Acquired anomalies, no congenital abnormality Tetralogy of Fallot (1)
Rheumatic heart disease (3) Complete atrioventricular canal (1)
Bacterial endocarditis (1) Acquired anomalies, no congenital abnormality
Bacterial endocarditis (1)
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Patients’ previous operative procedures and transcatheter
interventions are shown in Table 3. Autograft patients were
more likely to have had no interventions or balloon dilata-
tions without surgical procedures than allograft recipients.
Of the 17 patients who had undergone previous AVR, only
5 were able to undergo autograft AVR, including 2 patients
with previous Konno ventriculoplasties. The other 12 recip-
ients of a previous AVR had allografts implanted due to
technical reasons; this included 4 patients with previous
Konno procedures.
Surgical Procedures and Perioperative Results
All autograft and allograft AVRs were performed as root
replacements with coronary artery reimplantation and root
enlargement or reduction as necessary. Operations were
performed with moderate hypothermia (27°C) and ante-
grade and retrograde blood cardioplegia. For the autograft
group, the native pulmonary valves were replaced by 73
pulmonary and 5 aortic valve allografts ranging in size from
12 to 27 mm (median 22 mm). For the group receiving an
allograft AVR, 22 aortic valve allografts and 3 pulmonary
valve allografts were used, ranging in size from 17 to 27
mm (median 21 mm). Additional procedures beyond the
AVR were performed in 10 autograft recipients (4 Konno-
Rastan ventriculoplasty, 3 mitral valve replacement, 2 mi-
tral valve repair, and 1 coronary arterioplasty) and in 10
allograft recipients (8 pulmonary valve allograft replace-
ment, 1 mitral valve repair, and 1 aortic arch replacement).
There were 3 perioperative deaths, all in the autograft
group. Causes of death were hemorrhage in 1 patient, per-
sistent left ventricular outflow obstruction in 1 patient, and
pulmonary hypertension (which was present preoperatively)
in 1 patient. In no case did it appear that use of an allograft
would have altered these outcomes. Major complications in
the autograft group included 1 stroke and 3 cases of heart
block necessitating a pacemaker implant. Complications in
the allograft group included 1 stroke, 1 pacemaker, and 2
cases of mediastinitis. The median duration of hospitaliza-
tion for operative survivors was 5 days in both groups.
Follow-up
Information regarding the late status of patients was ob-
tained from medical records, office records of cardiologists
and primary care physicians, and personal contact with
patients and families. Follow-up could not be obtained for
only 17 patients in calendar year 2001, and overall fol-
low-up was 89.1% complete through October 1, 2001.
Late Results
One hundred patients were discharged alive after AVR.
There was 1 late death in an allograft recipient. Seven-year
actuarial survival was 96% in both groups (Figure 1).
Reoperations were performed in 5 autograft recipients,
all of whom had congenital aortic stenosis as their original
indication for AVR. One autograft recipient required re-
placement of the pulmonary valve allograft. The other 4
autograft reoperations were performed on the left ventricu-
lar outflow tract; in 2 cases for treatment of supravalvular
aortic dilatation (in both cases, the autograft valves were
preserved), in 1 for subvalvular obstruction (the autograft
valve was preserved), and in 1 for valvular insufficiency
(the autograft was replaced with an aortic valve allograft).
Reoperations were performed in 3 allograft recipients for
allograft valve deterioration (stenosis in 2, insufficiency in
1) and all required re-replacement of the valve (with another
allograft in 1 case and with a mechanical valve in 2 cases).
The 7-year actuarial reoperation-free survivals, 88% in the
autograft group and 73% in the allograft group, were not
significantly different (P  .5) (Figure 2).
In neither the autograft nor the allograft group were there
late complications of stroke, hemolysis, or endocarditis.
The data were analyzed to determine whether preopera-
tive factors correlated with outcomes. Of the following
variables, all failed to show a significant correlation with
operative mortality, morbidity, or need for late reoperation:
congenital cardiac anatomy, preoperative pathology (aortic
stenosis versus insufficiency), number of previous opera-
tions, patient age, patient weight, and previous balloon
valvotomy.
Echocardiographic Results
Immediate postoperative echocardiographic examinations
and subsequent examinations were available for 91 patients.
The follow-up studies were obtained from 1 to 80 months
postoperatively.
In the autograft group, left ventricular outflow tract
Vmax declined from an immediate postoperative level of
2.0  0.7 m/s to a most recent velocity of 1.8  0.7 m/s.
This difference is statistically significant (P  .02). In
allograft group, the Vmax increased from 2.3  0.8 m/s to
3.0 1.2 m/s. This difference is also statistically significant
(P  .03).
TABLE 2. Pathologic findings*
Autograft (n  78)
Aortic valve stenosis (13)
Aortic valve insufficiency (23)
Mixed valve stenosis and insufficiency (42)
Allograft (n  25)
Aortic valve stenosis (11)
Aortic valve insufficiency (12)
Mixed valve stenosis and insufficiency (2)
*The distribution of pathologic findings was significantly different, P 
.0002.
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In the autograft group, the mean left ventricular posterior
wall thickness declined between the immediate postopera-
tive period and latest follow-up from 10.1  2.4 mm to 8.4
 2.0 mm, again a statistically significant difference (P 
.0001). In the allograft group, the mean posterior wall
thickness in the immediate postoperative period, 9.5  2.2
mm, and the latest wall thickness, 9.0  2.0 mm, were not
significantly different (P  .2).
Echocardiographic findings of important valvular insuf-
ficiency as shown in Table 4 were uncommon in both
groups.
Discussion
The Ross procedure has become increasingly accepted as
the operation of choice for children requiring AVR. Some,
however, have questioned its routine application and be-
lieve the Ross procedure may be contraindicated for certain
patients. The Ross procedure is not a cure for aortic valve
disease. Beyond its technical demands, which are formida-
ble, there are legitimate concerns about long-term growth
and durability of the autograft,2,3 dilatation of the neoaortic
root,4 and fate of the pulmonary allograft. Ultimately, the
decision to perform the Ross procedure or an alternative
operation must be tempered to some degree by what that
alternative operation is. Bioprosthetic valves are known to
deteriorate even more rapidly in children than in adults, and
mechanical valves exhibit a surprisingly high frequency of
late complications and reoperations in pediatric patients.1,5
AVR with an allograft valve is 1 potential alternative.
The allograft shares several of the favorable qualities of the
autograft, including excellent immediate hemodynamics,
even in small sizes; freedom from a need for anticoagula-
tion; resistance to infection; and suitability for use despite
congenital or acquired distortions of cardiac anatomy. Be-
cause the native pulmonary valve is not disturbed, allograft
AVR is somewhat technically easier. It is possibly safer as
well, because the coronary circulation is at lower risk of
injury. Finally, an allograft AVR does not extend the range
of potential pathology to the right side of the heart, which is
inevitable with the Ross procedure. In a randomized trial,
allograft valves have been shown to be superior to stented or
stentless bioprosthetic valves in reducing left ventricular
hypertrophy.6 In adult populations, the allograft has shown
both immediate7 and longer-term8 success comparable with
that obtained with the autograft. Although the adult popu-
lation does not have growth as an issue, and thereby may be
TABLE 4. Postoperative echocardiographic grading of
valve insufficiency
Autograft Allograft
0-trace (36) 0-trace (9)
1 (46) 1 (11)
2 (2) 2 (5)
3-4 (1) 3-4 (0)
TABLE 3. Previous interventions
Autograft* Allograft†
Aortic valvotomy (34)
Subaortic stenosis repair (12)
Coarctation repair (12)
Aortic valve replacement (10 mechanical valves, 1
allograft, 1 autograft; 4 Konno ventriculoplasties) (12)
Aortic valvotomy (7)
VSD repair (8) Pulmonary valve replacement (5)
Aortic valve replacement (5 mechanical valves, 2
Konno ventriculoplasties) (5)
Mitral valve replacement (3)
Interrupted aortic arch repair (2)
Left-ventricle-aortic tunnel repair (2)
Supravalvar aortic stenosis repair (1)
Mitral valve repair (1)
VSD repair (3)
Subaortic stenosis repair (3)
Pulmonary artery band (2)
Tetralogy of Fallot repair (1)
Supravalvar aortic stenosis repair (1)
Mitral valve repair (1)
Repair of paravalvar leak (1)
Interrupted aortic arch repair (1)
David procedure (1)
Arterial switch (1)
Complete atrioventricular canal repair (1)
Modified Blalock-Taussig shunt (1)
Total: 80 operations in 48 patients‡
Total: 42 operations in 22 patient‡
VSD, Ventricular septal defect.
*No intervention in 15 patients; balloon dilatation only in 15 patients.
†No intervention in 3 patients.
‡Number of operations does not equal number of specific procedures due to multiple procedures during some operations.
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better served with allograft valves, there remains a concern
regarding progressive allograft deterioration, which may not
occur with the autograft.
The results of this investigation support the hypothesis
that the autograft AVR is the preferred approach for chil-
dren with unreconstructable aortic valves. Although both
autograft and allograft recipients have similarly good sur-
vival and freedom from valve-related complications at an
intermediate duration of follow-up, there are differences in
the hemodynamic trends. The autograft group displayed
better hemodynamics over time, with a small but statisti-
cally significant decline in left ventricular outflow tract
velocity. Whether this modest change is clinically important
is unknown. This contrasts, however, with the increase in
Vmax in the allograft group. It is likely that this difference
is attributable to 2 factors: (1) growth of the autograft,
which has been well described and which does not occur in
allografts, and (2) gradually progressive degeneration of the
allograft, which is probably inevitable to a greater or lesser
degree. In turn, these differences in left ventricular physi-
ology could explain the observed differences in left ventric-
ular morphology, with the reduced wall thickness found in
the autograft group reflecting the hemodynamic superiority
of this valve.
Obstacles to the uniform use of the autograft include
pulmonary valve congenital absence or deformity, which
are usually associated with specific forms of congenital
heart disease. This series had no instance of an unexpectedly
discovered anomaly of the pulmonary valve that precluded
its use as an autograft. Another situation in which the
autograft procedure is less desirable is in the patient with
Marfan syndrome. Although there is a paucity of data re-
garding the ultrastructure of the pulmonary valve and artery
in this syndrome, it should be assumed that autografting of
such a valve would likely lead to dilatation and a risk of
dissection. The results of allograft AVR in Marfan patients
are less than optimal as well, with 2 of the 4 Marfan patients
in this series undergoing allograft AVR eventually requiring
valve re-replacement. We currently prefer the David proce-
dure as a better approach for children’s with Marfan’s
syndrome.9 The major obstacle to autograft use in the
present series was previous surgical interventions that lim-
ited the ability to extract the pulmonary valve in a structur-
ally intact state. The greatest single cause of pulmonary
valve compromise was a prior Konno procedure, with 4 of
6 cases unable to undergo autograft AVR. It should be noted
also that even a relatively simple repair of an isolated
ventricular septal defect can result in patch placement con-
tiguous to the pulmonary valve, and this often makes pul-
monary valve retrieval quite demanding.
In the pediatric population, there have been few data
addressing the hypothesis that the autograft is superior to
the allograft in terms of clinical or hemodynamic outcomes.
One of the earliest studies that does address this found no
significant differences among children receiving autograft
or allograft AVRs with respect to valve-related deaths or
reoperation.2 This pioneering work, reflecting an earlier era
of technique and myocardial preservation methods, had a
relatively higher operative mortality than would be expected
today, and the ratio of autografts to allografts, approxi-
mately 1 to 3, was the inverse of that in the present series.
This study supports previous studies of autograft and
allograft AVR in adult populations that have found excel-
lent clinical outcomes from either operative technique. One
of the largest series addressing this issue demonstrated no
significant differences in survival, freedom from reopera-
tion, freedom from valve graft degeneration, and freedom
from all valve-related complications at 10 years after AVR.8
These authors also noted, however, that there is a trend
toward somewhat greater tissue degeneration in allografts
beyond 8 years, and concluded that this suggested a stronger
case for autograft use in younger patients. A large random-
ized trial of autografts and allografts in a mostly adult
population also found no significant differences based on
Figure 1. Actuarial survival. Figure 2. Reoperation-free survival.
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type of AVR employed.7 The maximum follow-up in that
series was only 21 months, however, and this may have
limited the opportunity to observe important differences.
The primary limitation of this study is the heterogeneity
of the patients and the greater complexity of the allograft
group. The very need for the use of the allograft, in a
practice in which the Ross procedure is preferred, is evi-
dence of a more difficult to manage subgroup of patients.
More rigidly controlled studies of autografts versus allo-
grafts are unlikely to be conducted. It is highly improbable
that a randomized trial would be considered ethically justi-
fiable in a pediatric population, given the considerable the-
oretical and proven advantages of the autograft. Other lim-
itations of this study include the unavoidable problems of
patient numbers and follow-up duration and completeness.
Offsetting these limitations is the routine use of human
valves in nearly all patients, with a less than 4% frequency
of mechanical valve use over an extended period of time.
Another value of this study is the series of detailed, sequen-
tial echocardiographic studies that permitted the detection
of subtle changes in left ventricular physiology and mor-
phology.
Whether the echocardiographic observations in this
study are harbingers of future clinical events is unknown. It
is generally accepted that reduction in left ventricular mass
is a desirable goal. Resolution of ventricular hypertrophy is
a slow and steady process that eventually produces im-
provement in objective measures of ventricular function and
symptomatic status.10-12 Conversely, failure to resolve ven-
tricular hypertrophy is associated with a lesser improvement
in symptoms and functional measurements as well as in-
creased risk of death.13-15 It is logical to conclude that a
more rapid and complete resolution of ventricular hypertro-
phy should be a factor in the type of aortic valve replace-
ment device that a surgeon selects.16
The existing literature combined with the favorable find-
ings in this study thus should support the confident use of
the allograft for pediatric patients when the autograft is not
an option. At the same time, this study should encourage the
use of the autograft AVR in children whenever possible
both to achieve the maximum hemodynamic benefits for the
myocardium and to favorably influence longer-term clinical
events.
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Discussion
Dr John A. Hawkins (Salt Lake City, Utah). Mark, first I
commend you and your colleagues on excellent results obtained in
this very difficult group of patients. Basically Dr Lupinetti and Dr
Duncan and their colleagues have reported a large series of chil-
dren undergoing AVR with both autografts and allografts, with
only a 3% operative mortality and a single late death and an
acceptable level of late morbidity. These are really admirable
numbers for a complex group of patients dating from what I would
assume is your first Ross procedure in 1994. From the outset I will
have to say I am really a true believer in the Ross procedure and
have no arguments with your approach. I would summarize your
message this morning as basically, do a Ross procedure when you
can and an allograft when you cannot. The significant findings you
showed us today were that the left ventricular outflow tract Vmax
basically increased in allografts and significantly decreased in the
autograft group, while left ventricular posterior wall thickness
decreased significantly in the autograft group and remained un-
changed in the allograft group.
My first question has to do with the finding in your series of this
significant increase in the Doppler-measured Vmax across the left
ventricular outflow tract. What was the follow-up in both groups of
patients? You stated that the follow-up was simply 1 to 80 months.
What is the problem with the allografts developing this late gra-
dient? Is it simply a time-related or growth phenomenon rather
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